| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention relates to field of medicine, namely to method of predicting preventive and/or therapeutic effect of RAR- agonist in oncological patients. In order to realise the method, level of expression of molecules of family p160, such as AIB1, SRC-1, TIF2, and level of expression of molecules of family SP110b in sample, taken from patient's malignant tumour, are determined and ratio between said levels of expression is determined. In case if ratio "level of AIB1 expression/ level of SP110b expression" is higher than 0.240, it is considered that RAR- agonist is efficient in therapeutic treatment of patient's malignant tumour. Similar conclusion is made if value of ratio "level of SRC-1 expression/ level of SP110b expression" exceeds 0.662, as well as in case if value of ratio "level of TIF2 expression/ level of SP110b expression" exceeds 0.141. In case if said values of ratio of expression levels is detected, patient is introduced RAR- agonist for treatment of malignant tumour, such as cancer of liver. ^ EFFECT: application of claimed method allows to predict efficiency of treatment with RAR- agonists quite accurately. ^ 10 cl, 5 tbl, 4 dwg |
